{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"description":"Adverse events will be determined by Events as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. The frequency of adverse events will be collected in tabular summary from when a participant consent to study until end of study or patient participant starts a new treatment.","groups":[{"description":"Selinexor\n\n• Given orally at a dose of 60 mg on days 1, 8, and 15 of a 28-day cycle.\n\nDexamethasone\n\n* Given orally at a dose of 40 mg on days 1, 8, 15 and 22 of a 28-day cycle.\n* Subjects will receive a prescription for dexamethasone 4 mg tablets (generic).\n\nClarithromycin\n\n* Given orally at a dose of 500 mg twice a day on days 1-28 of a 28-day cycle.\n* Subjects will receive a prescription for clarithromycin 250 or 500 mg tablets (generic) for oral administration.\n\nPomalidomide\n\n* Given orally at a dose of 4 mg daily on days 1-21 of a 28-day cycle.\n* Subjects will receive a 21-day supply of pomalidomide 1, 2, 3, or 4 mg capsules for oral administration for each treatment cycle.\n\nSelinexor: Given as 60 mg oral capsule\n\nClarithromycin: Given as 500 mg oral capsule\n\nPomalidomide: Given as 4 mg oral capsule\n\nDexamethasone: Given as 40 mg oral capsule","id":"OG000","title":"Selinexor, Clarithromycin, Pomalidomide and Dexamethasone (ClaSPd)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Adverse events were collected from time of informed consent until 30 days after the last day of study drug administration for each participant. The maximum period that AEs were collected for a participant was 300 days.","title":"Number of Participants With Adverse Events","type":"SECONDARY","unitOfMeasure":"Participants"}